All In Biotech

Drug Trial Radar · NCT06447597

A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 in Subjects With Generalized Myasthenia Gravis

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Jul 1, 2024

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Sponsor type
Industry
Collaborators
Shanghai Pharmaceuticals Holding Co., Ltd
First posted
Jun 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • B007Drug

    B007 high dose and low dose: Subcutaneous injection was administered on days 1 and 15

  • PlaceboDrug

    B007 matched Placebo Subcutaneous injection was administered on days 1 and 15

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects:MG-ADL(Myasthenia gravis-activities of daily living profile) decreased by ≥2Time frame: Approximately 16 weeks

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China · Recruiting

  • The First Bethune Hospital of Jilin University

    Changchun, China · Recruiting

  • Xiangya Hospital Central South University

    Changsha, China · Recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, China · Recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • Shandong Provincial Qianfoshan Hospital

    Jinan, China · Recruiting

  • Shandong University Cheeloo College of Medicine

    Jinan, China · Recruiting

  • First People's Hospital of Yunnan Province

    Kunming, China · Recruiting

  • Jiangxi Provincial People's Hospital

    Nanchang, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • Shandong University Cheeloo College of Medicine

    Qingdao, China · Recruiting

  • Huashan Hospital, Fudan University

    Shanghai, China · Recruiting

  • Shenzhen Hospital of University of Hong Kong

    Shenzhen, China · Recruiting

  • Renmin Hospital of Wuhan University

    Wuhan, China · Recruiting

  • Tongji Medical College of HUST

    Wuhan, China · Recruiting

  • Tangdu Hospital

    Xi'an, China · Recruiting

  • Affiliated Hospital of Zunyi Medical College

    Zunyi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.